LABT: LABT names David G. Armstrong Study Chair for Phase 2a Nu-3 iDFU trial

AI Summary

Lakewood-Amedex (LABT) appointed David G. Armstrong, a leading diabetic foot clinician, as Study Chair and Scientific Advisor for its Phase 2a proof-of-concept trial of topical Nu-3 in infected diabetic foot ulcers. The study will evaluate safety and efficacy of three topical concentrations (2%, 5%, 10%) to support a potential Phase 2b; no clinical data or timelines were disclosed and efficacy/safety remain unproven.

Positives

David G. Armstrong, a globally recognized diabetic foot expert, named Study Chair and Scientific Advisor
Phase 2a is a proof-of-concept trial testing three topical Nu-3 doses (2%, 5%, 10%) to inform a Phase 2b
Nu-3 is the company's lead Bisphosphocin® antimicrobial candidate targeting broad-spectrum and resistant bacteria (e.g., MRSA, VRE)

Negatives

Release announces a leadership appointment only; no clinical outcomes, start dates, or timelines provided
Phase 2a is early-stage—safety and efficacy are unproven and may not predict later success
Company disclaims typical forward-looking risks that trials may not be initiated, completed, or successful